Atlas Trials

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Clinical trial NCT02389985 · TERMINATED

Trial details

NCT number
NCT02389985
Sponsor
NewLink Genetics Corporation
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2015-07-01
Primary completion
2018-06-04
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.